Study: Most angioplasties unneeded

Posted by john on March 30th, 2007 — in Ultram News

NEW ORLEANS - More than half a million people a year with chest pain are getting an unnecessary or premature procedure to unclog their arteries because drugs are just as effective, suggests a landmark study that challenges one of the most common practices in heart care.
An even bigger surprise: Angioplasty gave only slight and temporary […]

Pain Relief Network (PRN) Questions Anna Nicole’s Autopsy Report: Drug Overdose, or Methadone-Induced Sudden Cardiac Death? Did Officials Draw an Erroneous Conclusion?

Posted by john on March 27th, 2007 — in Ultram News

SANTA FE, N.M., March 26 /PRNewswire/ — In a study published in Pain Relief Network’s peer-reviewed medical journal Illuminata, Dr. Frank Fisher looks at the alarming incidence of sudden cardiac death resulting from treatment with methadone. Go to: http://www.illuminatajournal.org/ “When Methadone and other medications are present in the blood of the deceased, medical examiners frequently […]

Biovail shares stuck in neutral despite healthy ‘pipeline’

Posted by john on March 23rd, 2007 — in Ultram News

Biovail Corp.’s stock price is stagnating because investors don’t see the value in the company’s pipeline of new products, chief executive Doug Squires said Thursday, as the drugmaker reported record earnings for 2006.
“Much of our pipeline is difficult to disclose and detail, because it contains so many proprietary ideas and technologies,” Squires said in an […]

Biovail profit hit by charges, outlook unchanged

Posted by john on March 17th, 2007 — in Ultram News

Biovail Corp. (BVF.TO: Quote) said on Thursday that it would maintain its 2007 forecast, despite a recent patent settlement that delays the flood of a generic version of its key Wellbutrin anti-depressant until 2008.
Canada’s biggest publicly traded drug company, which reported a lower fourth-quarter profit, reiterated its 2007 outlook for revenue of $800 million to […]

Biovail “outperform,” target price reduced

Posted by john on March 13th, 2007 — in Ultram News

Analyst Douglas Miehm of RBC Capital Markets maintains his “outperform” rating on Biovail Corp (BVF.NYS), while reducing his estimates for the company. The target price has been reduced from $24 to $23.
Drugs Online - Buy Drugs Online at reasanoble prices.DrugOnline.cc provides confortable and easy way to order drugs online including drugs free shipping.
In a research […]

Exploring Phantom Limb Pain

Posted by john on March 11th, 2007 — in Ultram News

First described more than 500 years ago, phantom limb pain (PLP) is a common disorder today; as many as 50% to 80% of patients who undergo amputation report experiencing pain in the missing body part.1 Although it is easy to recognize and diagnose, its cause remains unclear and it can be difficult to manage successfully. […]

When it comes to easing the pain, Ibuprofen best for children

Posted by john on March 6th, 2007 — in Ultram News

Research carried out in Canada on pain relief drugs for children has found that ibuprofen is more effective than either acetaminophen or codeine.
In a study of 300 children, aged 6 to 17 brought to the hospital emergency room with a broken bone or a serious sprain, the researchers found that a single dose of ibuprofen, […]

Biovail “outperform,” estimates reduced

Posted by john on March 2nd, 2007 — in Ultram News

NEW YORK, February 23 (newratings.com) - Analyst Douglas Miehm of RBC Capital Markets maintains his “outperform” rating on Biovail Corporation (BVF.NYS), while reducing his estimates for the company. The target price is set to $23.
Internet Pharmacy - Buy Pharmacy at reasanoble prices.Internet Pharmacy provides confortable and easy way to order pharmacy via internet.
In a research […]